Original Research
Published on 02 May 2023
Long-term outcomes of frontline imatinib therapy for chronic myeloid leukemia in China
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1172910
- 2,039 views
- 1 citation
Type at least 3 characters
1,687 articles
Articles
Original Research
Published on 02 May 2023
CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1150149
- 11,565 views
- 1 citation
Case Report
Published on 01 May 2023
Case Report: Infectious prophylaxis in hematological malignancies
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1163175
- 1,501 views
- 2 citations
Case Report
Published on 01 May 2023
B-cell lymphoblastic lymphoma following intravenous BNT162b2 mRNA booster in a BALB/c mouse: A case report
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1158124
- 154,888 views
- 4 citations
Review
Published on 28 Apr 2023
Challenges in nodal peripheral T-cell lymphomas: from biological advances to clinical applicability
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1150715
- 3,030 views
- 3 citations
Brief Research Report
Published on 28 Apr 2023
A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1157646
- 1,347 views
- 1 citation
Review
Published on 28 Apr 2023
Precise diagnosis and targeted therapy of nodal T-follicular helper cell lymphoma (T-FHCL)
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1163190
- 5,556 views
- 2 citations
Original Research
Published on 27 Apr 2023
Radiotherapy or chemotherapy: a real-world study of the first-time relapsed and refractory primary central nervous system lymphoma
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1098785
- 1,214 views
- 3 citations
Review
Published on 26 Apr 2023
Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1177590
- 8,277 views
- 7 citations
Original Research
Published on 26 Apr 2023
Misdiagnosis analysis of 2291 cases of haematolymphoid neoplasms
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1128636
- 2,101 views
- 1 citation
Original Research
Published on 25 Apr 2023
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1162990
- 2,863 views
- 2 citations
Review
Published on 24 Apr 2023
Management of B-cell lineage acute lymphoblastic leukemia: expert opinion from an Indian panel via Delphi consensus method
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1171568
- 6,948 views
- 3 citations
Case Report
Published on 21 Apr 2023
Case Report: Co-existence of a novel EXOC4‐TRHDE gene fusion with PML-RARA in acute promyelocytic leukemia
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1165819
- 1,119 views
Original Research
Published on 21 Apr 2023
Effects of ABVD chemotherapy on ovarian function: epidemiology, hormonal dosages and ultrasound morphologic analyses in 270 patients with Hodgkin’s disease
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1059393
- 2,302 views
Case Report
Published on 21 Apr 2023
Case Report: Rapid renal response to venetoclax monotherapy in a CLL patient with secondary membranous glomerulonephritis
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1108994
- 1,923 views
- 2 citations
Original Research
Published on 21 Apr 2023
Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1078725
- 2,399 views
- 2 citations